ValuEngine upgraded shares of OncoGenex Pharmaceuticals (NASDAQ:ACHV) from a strong sell rating to a sell rating in a research note released on Monday morning.

OncoGenex Pharmaceuticals (NASDAQ:ACHV) opened at $1.34 on Monday. OncoGenex Pharmaceuticals has a 12 month low of $1.25 and a 12 month high of $10.23.

OncoGenex Pharmaceuticals (NASDAQ:ACHV) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter.

TRADEMARK VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at

About OncoGenex Pharmaceuticals

Achieve Life Sciences, Inc, formerly OncoGenex Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for OncoGenex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.